Because hyperlipidemia is a classic feature of nephrotic syndrome, the fact that lorlatinib is apparently the only ALK-TKI reported to induce acute kidney injury involving renal cyst formation or progression suggests that minimal change disease (nephrotic syndrome) should be viewed as a possible secondary cause of lorlatinib-induced hyperlipidemia [42,43,44,45]. This evidence concerns the gene ALK and Renal cyst.